By Gabriel Paijo 
The landscape of oncology is witnessing a potential paradigm shift as researchers at the Medical University of South Carolina (MUSC) Hollings Cancer Center unveil a novel therapeutic approach to treating one of the most recalcitrant forms of malignancy: triple-negative breast cancer (TNBC). Published in the journal Breast Cancer Research, the study details the development of a humanized monoclonal antibody that targets a specific protein, secreted frizzled-related protein 2 (SFRP2), effectively dismantling the protective environment that allows aggressive tumors to flourish and resist conventional treatments.
Triple-negative breast cancer represents approximately 10% to 15% of all breast cancer cases but accounts for a disproportionately high number of deaths. It is defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). This "triple-negative" status means that common targeted therapies, such as tamoxifen or trastuzumab, are ineffective. Historically, patients have relied on a combination of surgery, radiation, and systemic chemotherapy. While many patients initially see a reduction in tumor size, the high rate of recurrence and the development of multidrug resistance remain significant hurdles in clinical practice.
The Role of SFRP2 in the Tumor Microenvironment
The focal point of this new research is the SFRP2 protein, a molecule that the research team has identified as a master regulator of tumor progression. Unlike many cancer treatments that target the DNA of the cancer cell itself, this antibody addresses the tumor microenvironment—the complex ecosystem of blood vessels, signaling molecules, and immune cells that surround and support a tumor.
SFRP2 has been found to facilitate three primary "survival strategies" for TNBC. First, it promotes angiogenesis, the process by which tumors grow new blood vessels to secure a nutrient and oxygen supply. Second, it inhibits apoptosis, the natural process of programmed cell death that should, under normal circumstances, eliminate mutated cells. Third, and perhaps most crucially in the context of modern oncology, it suppresses the local immune response, effectively creating a "shield" that prevents the body’s natural defenses from recognizing and attacking the malignancy.
The study’s lead author, Nancy Klauber-DeMore, M.D., a breast surgical oncologist and co-leader of the Developmental Cancer Therapeutics Research Program at Hollings, noted that SFRP2 is not just a byproduct of cancer but an active enabler. By blocking this protein, the research team found they could simultaneously stunt tumor growth and "re-educate" the immune system to resume its surveillance duties.
A Two-Decade Chronology of Discovery
The development of the SFRP2 antibody is not an overnight success but the culmination of nearly 20 years of rigorous scientific inquiry. The timeline of this discovery highlights the slow, methodical nature of translational medicine:
- 2008: Dr. Klauber-DeMore’s laboratory first identified SFRP2 as a highly expressed protein in the blood vessels of breast cancer tumors. This initial discovery suggested the protein might be a viable target for anti-angiogenic therapy.
- 2010–2015: Subsequent studies expanded the understanding of SFRP2, revealing its role in protecting cancer cells from the stresses of chemotherapy and hypoxia (low oxygen).
- 2016–2020: The team shifted focus toward the immune system, discovering that SFRP2 was present not only in the tumor cells but also in the surrounding stroma and immune infiltrates. This led to the engineering of a humanized monoclonal antibody—a precision tool designed to be compatible with the human immune system.
- 2021–2024: Preclinical testing in advanced animal models demonstrated the antibody’s ability to reduce metastasis and overcome resistance to standard chemotherapies like doxorubicin.
This long-term commitment has allowed the team to move beyond a simple "kill the cell" strategy toward a more sophisticated "re-engineer the environment" approach.
Reprogramming Macrophages and Restoring T-Cell Vitality
One of the most significant findings in the recent study involves the reprogramming of tumor-associated macrophages (TAMs). In the world of immunology, macrophages are often categorized into two polar states: M1 and M2. M1 macrophages are pro-inflammatory and anti-tumor, acting as the "soldiers" of the immune system. Conversely, M2 macrophages are anti-inflammatory and pro-tumor, often helping the cancer to repair itself and hide from other immune cells.
In aggressive TNBC, the tumor microenvironment typically forces macrophages into the M2 state. The research team discovered that SFRP2 is expressed on these tumor-associated macrophages, a finding that had never been documented before. When the experimental antibody was administered, it triggered a release of interferon-gamma. This signaling molecule acted as a biological switch, pushing the macrophages from the "bad" M2 state back into the "good" M1 state.
Furthermore, the treatment addressed "T-cell exhaustion." In chronic cancer cases, T-cells—the primary attackers of the immune system—often become fatigued and lose their ability to kill cancer cells. The SFRP2 antibody was shown to revive these cells, potentially making the tumor more susceptible to other forms of immunotherapy, such as checkpoint inhibitors (e.g., pembrolizumab), which have seen limited success in TNBC compared to other cancers.
Quantitative Success in Metastasis and Resistance
The preclinical data provided by the MUSC team offers compelling evidence of the antibody’s efficacy. In mouse models of advanced TNBC, those treated with the SFRP2 antibody showed a marked reduction in lung metastases. This is a critical metric, as the spread of TNBC to the lungs and brain is the primary cause of mortality in human patients.
Beyond preventing spread, the antibody demonstrated a unique ability to bypass chemotherapy resistance. Doxorubicin, often referred to as "the red devil" due to its color and toxicity, is a staple of TNBC treatment. However, tumors often evolve to pump the drug out of their cells or repair the damage it causes. The MUSC study found that even in cancer cells that had become completely resistant to doxorubicin, the SFRP2 antibody remained lethal to the tumor.
Importantly, the antibody demonstrated high specificity. Using tracking technology, the researchers observed that the antibody accumulated almost exclusively in tumor tissue. Unlike traditional chemotherapy, which circulates throughout the body and damages healthy cells in the hair follicles, gut, and bone marrow, the SFRP2 antibody left healthy organs untouched. This suggests that the treatment could have a much more favorable side-effect profile than current standard-of-care options.
Strategic Implications and the Path to Clinical Trials
The implications of this research extend beyond breast cancer. The FDA has already granted Rare Pediatric Disease and Orphan Disease designations to the SFRP2 antibody for its potential use in osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. Like TNBC, osteosarcoma is known to overexpress SFRP2, suggesting that this antibody could serve as a platform technology for multiple "hard-to-treat" cancers.
The technology has been licensed to Innova Therapeutics, a biotechnology firm co-founded by Dr. Klauber-DeMore. The company is currently focused on the manufacturing and regulatory hurdles required to initiate a Phase I clinical trial. These first-in-human trials will be essential to determine the optimal dosage and confirm that the safety profile observed in animal models translates to human patients.
Industry analysts suggest that if the SFRP2 antibody succeeds in clinical trials, it could become a cornerstone of "combination therapy." By softening the tumor’s defenses and activating the immune system, the antibody could be administered alongside low-dose chemotherapy or existing immunotherapies to produce a synergistic effect that is both more effective and less toxic.
A New Frontier in Precision Oncology
The work at MUSC Hollings Cancer Center represents a growing trend in precision oncology: the move toward "multi-modal" targeting. By identifying a single protein that controls multiple pathways of cancer survival—angiogenesis, immune evasion, and drug resistance—researchers have found a "master key" that could unlock new possibilities for patients who have exhausted all other options.
While the scientific community remains cautious—acknowledging that many promising preclinical results fail to bridge the "valley of death" between the lab and the clinic—the depth of the data and the 20-year history of the SFRP2 project provide a solid foundation for optimism.
As Dr. Lillian Hsu, a surgical resident involved in the study, noted, the goal is to provide a therapy that is as kind to the patient as it is ruthless to the cancer. For the thousands of women diagnosed with triple-negative breast cancer each year, this research represents more than just a laboratory success; it represents a tangible hope for a future where a TNBC diagnosis is no longer synonymous with a limited prognosis.
The next few years will be pivotal as the SFRP2 antibody moves into the clinical arena. If the results hold, the "re-engineering" of the immune system could become a standard pillar of cancer care, turning the tide against some of the most aggressive diseases known to modern medicine.